ReachMD

Be part of the knowledge.™

Rheumatology

116

LikeLikedUnlike

Episodes 16-25 of 25

Center of the Target: Which Patients Are Most Likely to Develop Gout?
MinuteCE®
Center of the Target: Which Patients Are Most Likely to Develop Gout?
- Richard Johnson, MD
  Peer
- Abdul Abdellatif, MD, FASN
  Peer
1.00 program credits
What’s New About Gout? Nephrology Perspective
MinuteCE®
What’s New About Gout? Nephrology Perspective
- Abdul Abdellatif, MD, FASN
  Peer
- Richard Johnson, MD
  Peer
1.00 program credits
Is Managing Gout in the Nephrology Clinic a Challenge?
MinuteCE®
Is Managing Gout in the Nephrology Clinic a Challenge?
- Richard Johnson, MD
  Peer
- Abdul Abdellatif, MD, FASN
  Peer
1.00 program credits
Is Gout Hiding in the Nephrology Clinic?
MinuteCE®
Is Gout Hiding in the Nephrology Clinic?
- Abdul Abdellatif, MD, FASN
  Peer
- Richard Johnson, MD
  Peer
1.00 program credits
Should We Look for Gout in the Cardiology Clinic?
MinuteCE®
Should We Look for Gout in the Cardiology Clinic?
- Richard Johnson, MD
  Peer
- Brittany Weber, MD, PhD
  Peer
1.00 program credits
Can We Do Better in IgAN?
CME/CE
Can We Do Better in IgAN?
- Jonathan Barratt, PhD
  Peer
- Annette Bruchfeld, MD, PhD
  Peer
0.25 credits
Understanding IgAN & FSGS: Pathophysiology and Emerging Therapies
CME/CE
Understanding IgAN & FSGS: Pathophysiology and Emerging Therapies
- Jonathan Barratt, PhD
  Peer
- Donald E. Kohan, MD, PhD
  Peer
0.50 credits
Case-Based Management of AAV
CME/CE
Case-Based Management of AAV
- David Jayne, MD
  Peer
- Annette Bruchfeld, MD, PhD
  Peer
Updates in Glomerular Disease
CME/CE
Updates in Glomerular Disease
- Jürgen Floege, MD
  Peer
- Jonathan Barratt, PhD
  Peer
- David Jayne, MD
  Peer
Pinpointing the Top Questions about Biosimilars in Rheumatology
Rheumatology
Pinpointing the Top Questions about Biosimilars in Rheumatology
- Leonard H. Calabrese, DO
  Peer
- John R. Tesser, MD
  Peer

Program Chapters

Segment Chapters

Playlist:

Recommended